Simvastatin slow-release tablet and preparation method thereof

Abstract

The invention provides a simvastatin slow-release tablet and a preparation method thereof. The simvastatin slow-release tablet comprises a medicine-carrying tablet core and a coating layer coated outside the medicine-carrying tablet core, wherein the medicine-carrying tablet core comprises the following raw materials according to parts by weight: 7-13 parts of simvastatin, 120-140 parts of filler and 40-60 parts of adhesive; the existing short-acting simvastatin tablet is prepared into a coating type slow-release preparation form which controls the diffusion and dissolution of a medicine so as to delay the release of the medicine; after the medicine enters a human body, the coating layer slowly dissolves, so that the medicine is stably and durably released, the blood concentration is kept in a more stable effective state for a long time, the defect of large fluctuation of the effective blood concentration caused by the overlarge fluctuation of the blood concentration existing in the frequent administration of a conventional preparation form is avoided, and the toxic or side effect is reduced; and the simvastatin slow-release tablet is prepared in a closed one-step boiling granulator, thereby being hardly polluted, the quality of a finished product can be better guaranteed, and automatic control is convenient.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations and relates to a chemical drug, in particular to a simvastatin sustained-release tablet and a preparation method of the sustained-release tablet. Background technique [0002] Simvastatin is a reductase inhibitor of methylhydroxyglutaryl coenzyme A (HMG-COA), inhibits the synthesis of endogenous cholesterol, and is a blood lipid regulator. Literature data show that simvastatin has the content of reducing cholesterol (TC) in hyperlipidemic rabbit serum, liver and aorta, reducing very low-density lipoprotein cholesterol (VLDL-C) and low-density lipoprotein cholesterol (LDL-C). C) Effect of levels. Simvastatin is highly selective to the liver after oral administration, and its concentration in the liver is significantly higher than that in other non-target tissues. Most of simvastatin is absorbed through the liver tissue and converted into the active metabolite β-hydroxy acid str...

AI Technical Summary

Problems solved by technology

[0004] But when simvastatin plays a therapeutic role, because the existing simvastatin dosage forms are common preparations, they are all short-acting dosage forms, and there are following defects when administering: due to the short half-life of the short-acting dosage forms, the drug effect time is short , in order to give full play to its therapeutic effect, it needs to be administered several times a day, which is likely to cause large fluctuations in blood drug concentration, leading to side effects such as headache, tachycardia, palpitations, and dizziness